GENPREX INC (GNPX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.50+2.04%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Manage operating losses near $4.46M per quarter: metric not reported.
Genprex is advancing clinical research on its cancer gene therapy. It has secured patents to protect its technology. Cash burn has improved from negative $5.8M to negative $3.14M per quarter. The company is working to control losses around $4.46M per quarter.
Genprex remains unprofitable with ongoing net losses near $4.5M per quarter. Recent legal and regulatory issues, including delisting risk, weigh on the stock. Clinical progress is slow and uncertain. Cash burn, though improved, is still negative and a concern.
The market is selling off sharply, reflecting high risk and uncertainty. There is no clear consensus revenue or EPS growth priced in. Our view is cautious given ongoing losses and legal risks.
Breaks if: cash burn worsens below -$4M per quarter next year
Control operating expenses and cash flow to manage ongoing net losses and negative cash from operations.
Stated as a priority in 8 of last 8 quarters. Operating income remained negative, ranging from -$4.68M in 2025-Q2 to -$4.48M in 2026-Q2, while cash from operations worsened from -$2.19M in 2024-Q3 to -$5.14M in 2026-Q2. Management continues to manage losses but financials show persistent negative cash flow and operating losses, indicating limited progress on reducing burn.
“Operating income was -$4.48M and cash from operations was -$5.14M.”
“Operating income was -$4.49M and cash from operations was -$3.14M.”
“Operating income was -$3.52M and cash from operations was -$4.10M.”
“Operating income was -$3.35M and cash from operations was -$3.19M.”
“Operating income was -$4.68M and cash from operations was -$3.86M.”
“Operating income was -$3.97M and cash from operations was -$4.16M.”
“Operating income was -$4.34M and cash from operations was -$3.87M.”
“Operating income was -$4.32M and cash from operations was -$2.19M.”
Breaks if: progress score falls below 30% next year
Continue clinical trials and research collaborations to develop Reqorsa Gene Therapy for lung cancer treatment.
Stated as a priority in 4 of last 4 quarters. While no revenue is reported, management has consistently emphasized advancing clinical development through collaborations and patent expansions. The trajectory shows persistent focus with positive research milestones but no commercial revenue yet.
“Announced collaboration with Roche Diagnostics to validate biomarkers for NSCLC clinical trials.”
“Research collaborators presented positive clinical data for Reqorsa Gene Therapy at ASCO 2026.”
“Issued patent covering Reqorsa Gene Therapy in combination with PD-1 antibodies for cancer treatment.”
“Research collaborators to present positive preclinical data on diabetes gene therapy at ASGCT 2026.”
Breaks if: loss of key patents or IP rights
Secure patents and expand IP rights to support drug candidates and collaborations.
Stated as a priority in 3 of last 4 quarters. Management has secured multiple patents expanding the intellectual property portfolio for Reqorsa Gene Therapy. While no direct financial impact is reported, the company is actively protecting and expanding IP rights, showing consistent delivery on this priority.
“Patent issued covering Reqorsa Gene Therapy with PD-1 or PD-L1 antibodies for lung cancer treatment.”
“Israel Patent Office granted patent expanding Company's intellectual property portfolio.”
“Patent granted for use of Reqorsa Gene Therapy in combination with PD-1 antibodies.”
Breaks if: net loss exceeds $5M per quarter next year
Control operating expenses and cash flow to manage ongoing net losses and negative cash from operations.
Stated as a priority in 8 of last 8 quarters. Operating income remained negative, ranging from -$4.68M in 2025-Q2 to -$4.48M in 2026-Q2, while cash from operations worsened from -$2.19M in 2024-Q3 to -$5.14M in 2026-Q2. Management continues to manage losses but financials show persistent negative cash flow and operating losses, indicating limited progress on reducing burn.
“Operating income was -$4.48M and cash from operations was -$5.14M.”
“Operating income was -$4.49M and cash from operations was -$3.14M.”
“Operating income was -$3.52M and cash from operations was -$4.10M.”
“Operating income was -$3.35M and cash from operations was -$3.19M.”
“Operating income was -$4.68M and cash from operations was -$3.86M.”
“Operating income was -$3.97M and cash from operations was -$4.16M.”
“Operating income was -$4.34M and cash from operations was -$3.87M.”
“Operating income was -$4.32M and cash from operations was -$2.19M.”
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state is cautious due to persistent losses and volatility in management, which raises concerns about future performance.
The market appears to have priced in high risk and uncertainty, given the company's weak recent financial performance compared to its peers. Expectations may be low, particularly with the elevated probability of an earnings miss in the near term.
Fundamentals are likely to remain under pressure as GNPX continues to report operating losses and negative cash flow. Management's focus on advancing clinical development and managing cash burn has not yet translated into commercial success.
The long-term thesis hinges on the performance of sector bellwethers and the company's ability to advance its gene therapy program. Any favorable developments in the healthcare sector could provide a boost, while negative trends could further weigh on GNPX.
Over the next 1 to 3 years, GNPX's prospects will depend heavily on its clinical advancements and the broader healthcare market dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.